Cell-Penetrating Peptide Enhances Tafazzin Gene Therapy in Mouse Model of Barth Syndrome
Author Information
Author(s): Raghav Rahul, Awata Junya, Martin Gregory L., Strathdee Douglas, Blanton Robert M., Chin Michael T.
Primary Institution: Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, USA
Hypothesis
The addition of a cell-penetrating peptide may improve TAFAZZIN gene therapy.
Conclusion
A cell-penetrating peptide enhances gene therapy for Barth Syndrome by improving cardiac function.
Supporting Evidence
- The addition of penetratin did not significantly affect the cardiolipin remodeling activity of TAFAZZIN.
- Treatment with hTAFAZZIN-Antp improved cardiac function compared to controls.
- Serial echocardiograms showed significant differences in heart function between treated and untreated mice.
Takeaway
Researchers found that adding a special peptide helps a gene therapy work better in mice with Barth Syndrome, which is a serious heart condition.
Methodology
The study involved treating TAFAZZIN knockout mice with lentiviruses expressing different forms of tafazzin and assessing cardiac function and cardiolipin remodeling.
Limitations
The study was conducted in a mouse model, which may not fully replicate human conditions.
Participant Demographics
33 male TAFAZZIN knockout mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website